The impact of antidepressant treatment on cognitive functioning in depressed patients with Parkinson's disease

Document Type

Article

Abstract

Depression is associated with more rapid cognitive decline in Parkinson's disease. The goal of this study was to examine the impact of the acute (8-week) and longer-term (24-week) antidepressant treatment on cognition in Parkinson's disease and to detail cognitive predictors of treatment response. Fifty-two depressed Parkinson's disease patients were enrolled in an NIH-funded randomized, controlled trial of nortriptyline, paroxetine, and placebo. Neuropsychological testing was performed at baseline and weeks 8 and 24. Higher baseline scores on measures of executive functioning, speed of processing, and verbal memory were associated with antidepressant response. Treatment responders did not exhibit larger gains in cognition than nonresponders. Findings warrant replication.

Medical Subject Headings

Adult; Aged, 80 and over; Antidepressive Agents (administration & dosage, therapeutic use); Antidepressive Agents, Second-Generation (administration & dosage, therapeutic use); Antidepressive Agents, Tricyclic (administration & dosage, therapeutic use); Cognition Disorders (complications, drug therapy); Depressive Disorder (complications, drug therapy); Double-Blind Method; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Nortriptyline (administration & dosage, therapeutic use); Parkinson Disease (complications, drug therapy); Paroxetine (administration & dosage, therapeutic use); Time Factors; Treatment Outcome

Publication Date

1-1-2010

Publication Title

The Journal of neuropsychiatry and clinical neurosciences

E-ISSN

1545-7222

Volume

22

Issue

2

First Page

188

Last Page

95

PubMed ID

20463113

Digital Object Identifier (DOI)

10.1176/appi.neuropsych.22.2.188

This document is currently not available here.

Share

COinS